CC
Chemours CoPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Jun 3 ▲ The Fourth Circuit vacated a preliminary injunction that had barred…
- Aug 4 ▼ Chemours reported Q1 2026 EPS of $0.05, missing consensus of $0.42 b…
- Aug 6 to Aug 12 ▲ 4 days of insider buys: $488.6K by 7 insiders, avg $15.49
- Aug 10 ▼ UBS downgrades
- Sep 10 ▲ Chemours, along with DuPont and Corteva, entered into a $455 million…
- Oct 13 Barclays initiates
- Oct 14 ▼ Mizuho downgrades
- Nov 2 ▼ Earnings: CC Q3 2026 Earnings: EPS $0.21 (-23.4% vs est)
Signal stack
Where each data set points today.
- InsidersBULLISH
7 insiders bought $488.6K at an average $15.49. No open-market sales. Price is 19% below their cost.
- InstitutionsBULLISH
Q3 2026: 35 added (2 new), 20 trimmed or exited. Largest new: Hrt Financial $12.4M.
- AnalystsBULLISH
11 of 20 rate it Buy or better. Every target is above the price.
- Short sellersSTEADY
Short interest −2.1% to 14.54M shares. 6.8 days to cover, ≈9.7% of shares.
- TrendDOWNTREND
9% below its 50-day average.
- SocialQUIET
No Reddit mentions this week. Last mention Nov 2.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| JPMORGAN CHASE & CO | ADD | $80.2M |
| Jefferies Financial Group Inc. | DOUBLED | $37.2M |
| AMERICAN CENTURY COMPANIES INC | TRIM | $28.1M |
| HRT FINANCIAL LP | NEW | $12.4M |
| UBS Group AG | TRIM | $10.0M |
| Quantinno Capital Management LP | ADD | $9.3M |
| BANK OF MONTREAL /CAN/ | TRIM | $8.4M |
| CAPITAL FUND MANAGEMENT S.A. | ADD | $5.1M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
20 analystsPrice is below the lowest target. Median implies +24%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 9, 2026 | JP Morgan MAINTAIN | Neutral |
| Nov 4, 2026 | UBS MAINTAIN | Neutral |
| Nov 4, 2026 | Truist Securities MAINTAIN | Buy |
| Oct 20, 2026 | Truist Securities MAINTAIN | Buy |
| Oct 14, 2026 | Mizuho DOWNGRADE | Neutral |
| Oct 13, 2026 | Barclays INITIATE | Equal-Weight |
Washington
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
MATHER COURTNEY Director Sep 30, 2026 | AWARD | $28.7K |
Will David Chief Accounting Officer Aug 12, 2026 | TAX W/H | $37.0K |
Familiar Calderon Gerardo See Remarks Aug 12, 2026 | BUY | $30.1K |
Dignam Denise Chief Executive Officer Aug 11, 2026 | BUY | $50.5K |
CRANSTON MARY B Director Aug 7, 2026 | BUY | $95.0K |
Cowan Alister Director Aug 7, 2026 | BUY | $203.1K |
Foley Michael Robert See Remarks Aug 7, 2026 | BUY | $30.0K |
Martinko Joseph T. See Remarks Aug 7, 2026 | BUY | $30.0K |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
18 filings · 2 bullish · 4 bearish · 2 mixed · 10 neutral- MIXED INST-CLUSTERNov 5, 2026
Institutional activity in Chemours during Q3 2026 was mixed: 4 small asset managers added $809K in…
The cluster shows a clear divergence: small asset managers added modestly while Citigroup's near-exit dominates the dollar flow. Monitor next 13F for whether the selling broadens or stabilizes, and…
- NEUTRAL 10-K/ANov 3, 2026
Chemours filed Amendment No. 1 to its 2025 10-K solely to correct an administrative error…
The disclosure controls weakness was remediated by Q3 2026, and the auditor's ICFR opinion was unqualified. No financial restatement or material weakness was identified. Monitor next 10-Q for…
- BEARISH 8-KNov 2, 2026
Chemours reported Q3 2026 adjusted EPS of $0.21, missing the $0.26 consensus, on revenue of…
The lowered full-year adjusted EBITDA guidance and the TSS segment weakness are the primary negatives. Monitor Q4 2026 results for TSS volume recovery and any further guidance revisions, as well as…
- BEARISH PRESS-RELEASENov 2, 2026
Chemours reported Q3 2026 adjusted EPS of $0.21, below the $0.26 consensus, while net sales of…
The Q3 adjusted EPS miss and weak Q4 guidance (Adjusted EBITDA $160M-$185M, implying a sequential decline) suggest continued headwinds in the TSS stationary AC aftermarket. Monitor the Q4 earnings…
All CC filing & press-release reports (18)
- INST-CLUSTER reportNov 5, 2026
- 10-K/A reportNov 3, 2026
- 8-K reportNov 2, 2026
- PRESS-RELEASE reportNov 2, 2026
- PRESS-RELEASE reportOct 27, 2026
- PRESS-RELEASE reportOct 21, 2026
- 8-K reportSep 10, 2026
- 8-K reportSep 9, 2026
- INST-CLUSTER reportAug 14, 2026
- CLUSTER reportAug 13, 2026
- CLUSTER reportAug 11, 2026
- PRESS-RELEASE reportAug 4, 2026
- PRESS-RELEASE reportAug 4, 2026
- PRESS-RELEASE reportJul 23, 2026
- COURT-RULING reportJun 3, 2026
- 8-K reportMay 5, 2026
- 8-K reportApr 29, 2026
- DEFA14A reportMar 10, 2026